Table 1.
Baseline characteristics of participants
| Mepolizumab | Omalizumab | |
|---|---|---|
| N | 22 | 29 |
| Age in years, mean (SD) | 57.2 (11.6) | 42.0 (15.3) |
| Female, n (%) | 15 (68) | 23 (79) |
| White race, n (%) | 17 (77) | 26 (90) |
| Current smoker, n (%) | 1 (4.5) | 0 (0.0) |
| Former smoker, n (%) | 5 (22.7) | 3 (10.3) |
| BMI, kg/m2; mean (SD) | 30.5 (6.6) | 28.2 (7.5) |
| Baseline annualized exacerbation rate, mean (SD) | 2.4 (2.0) | 1.5 (1.6) |
| Blood eosinophil counts, cells/µL; median [IQR] | 269 [90–395]a | 121 [78–247] |
| Immunoglobulin E (IgE), IU/µL; median [IQR] | 213 [44–482] | 92 [45–281]b |
| Allergic rhinitis, n (%) | 19 (86) | 29 (100) |
BMI, Body mass index; IQR, interquartile range; SD, standard deviation
aAll patients with eosinophil count of < 150 cells per mcl at baseline visit had counts above 150 at least once in the year prior to mepolizumab initiation
bTwo patients who started omalizumab for asthma and met other criteria for omalizumab were missing baseline IgE